I. Transaction Overview
Kweichow Moutai Group Co., Ltd. (hereinafter referred to as "the Company") held the fifteenth meeting of the fifth board of directors on December 30, 2025, and approved the proposal regarding the acquisition of market authorization and related technology for Mesalazine Enteric-Coated Tablets by its wholly-owned subsidiary, Jiamusi Luling Pharmaceutical Co., Ltd. (hereinafter referred to as "Luling Kweichow"). To further enrich the product pipeline, continuously consolidate the company's advantageous position in gastrointestinal medications, and enhance the overall risk resistance capability, the company agreed to acquire the market authorization and related production technology for Mesalazine Enteric-Coated Tablets (0.5g specification) from Hefei Cube Pharmaceutical Co., Ltd. for RMB 34 million (including tax). Specific details can be found in the announcement disclosed by the company on December 31, 2025, in the Securities Daily, Shanghai Securities News, and the Giant Tide Information Network (http://www.cninfo.com.cn) (Announcement No. 2025-084).